|
|
 |
JACI Highlights - March 2007
Martel et al – Use of short-acting beta2-agonists during pregnancy and the risk of pregnancy-induced hypertension
Studies have suggested a possible protective association of inhaled short-acting beta2-agonists on pregnancy-induced hypertension in women with asthma. In the March 2007 issue of the Journal of Allergy and Clinical Immunology, Martel and colleagues report a study testing the effect of inhaled short-acting beta2-agonists in women with asthma who develop pregnancy-induced hypertension. The authors found that compared with non-use, the use of inhaled short-acting beta2-agonists during pregnancy was significantly associated with a reduced risk of pregnancy-induced hypertension. These results add to growing evidence that inhaled short-acting beta2-agonist use is safe for pregnant women. Practitioners should, however, always keep in mind the importance of maintaining good control of asthma when making prescribing decisions.
<back>
|
